echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > It's time for China to innovate! Professor Cheng Ying and ASTRUM-005 research were listed in international authoritative journals, refreshing the survival height of SCLC

    It's time for China to innovate! Professor Cheng Ying and ASTRUM-005 research were listed in international authoritative journals, refreshing the survival height of SCLC

    • Last Update: 2023-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 27, 2022, Beijing time, JAMA (Journal of the American Medical Association, impact factor 157.
    335), one of the four top medical journals, published the full text online by Cheng Ying of Jilin Cancer Hospital Results of ASTRUM-005 (NCT04063163)1 in the global multicenter phase III clinical study of serplulimab (HLX10) in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
    led by the professor.


    The results of the study showed that the median overall survival (OS) of serplulimab combined with chemotherapy first-line was 15.
    4 months, reaching an unprecedented survival height
    .
    The inclusion of ASTRUM-005 in JAMA is a breakthrough for the change of ES-SCLC treatment pattern
    .
    It is worth mentioning that this is the ASTRUM-005 research after being featured in the oral report of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting once again on the international academic stage, which shows that the gold content of the study and its important value to the SCLC field in China and even the world, it is the beginning of Chinese researchers leading SCLC immunotherapy to a better way, and it is also a microcosm of the rapid development of China's innovative pharmaceutical companies!


    Beyond endlessly! The median OS was 15.
    4 months, and the OS HR was 0.
    63, exploring a new height of ES-SCLC survival


    Treatment of SCLC has been slow to develop over the past 30 years, with platinum-based drugs plus etoposide chemotherapy regimens dominating
    .
    The development of immunotherapy has brought about a turnaround in lung cancer treatment, but unlike non-small cell lung cancer (NSCLC), immunotherapy has made few advances in the field of SCLC
    .
    Previous research data suggest that PD-L1 inhibitors can only prolong the survival of patients with ES-SCLC by about 2 months, while PD-1 inhibitors have mostly failed in the exploration of first-line treatment of ES-SCLC2-5
    .
    Therefore, improving overall survival of ES-SCLC remains the most urgent clinical unmet need
    .


    The ASTRUM-005 study is the first international multicenter clinical study led by Chinese investigators to conduct the largest PD-1 inhibitor for ES-SCLC indications, aiming to compare the efficacy and safety
    of serplulimab and placebo in the first-line treatment of ES-SCLC with standard chemotherapy (EC regimen: carboplatin + etoposide), respectively.
    A total of 585 patients were included in the study, of which 400 (68.
    4%) were Chinese patients
    .
    The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), safety, and immunogenicity
    .


    The results showed that serplulimab combined with chemotherapy significantly prolonged the patient's OS, becoming the first PD-1 inhibitor
    in the world to achieve a positive result in first-line treatment of ES-SCLC 。 The median OS of the serplulimab group was 15.
    4 months, which was 4.
    5 months longer than that of the control group of 10.
    9 months, with an HR of 0.
    63 (95% CI 0.
    49-0.
    82; P < 0.
    001), and a significant reduction in the risk of death by 37%, which is the longest clinical study in all first-line immunological ES-SCLC studies, and the OS HR value also stands out
    among other similar studies 。 In addition, the 2-year OS rate of 43.
    1% in the serplulimab group and only 7.
    9% in the control group meant that more than two-fifths of patients could survive for more than 2 years
    with serplulimab regimen.



    Figure OS analysis


    Reap the benefits across the board! Multiple positive results of PFS, ORR, and DOR show China's strength and lead the global breakthrough


    In addition to the primary endpoint OS, serplulimab also brings the full range of PFS, ORR, and OR benefits
    .
    The median PFS was 5.
    7 months versus 4.
    3 months, PFS HR 0.
    48, and the risk of disease progression or death was reduced by 52%.

    PFS HR in previous studies of the same type was around 0.
    80, and PFS HR in ASTRUM-005 achieved a breakthrough of less than 0.
    50, suggesting that serplulimab also has unique advantages
    in delaying disease progression.
    In addition, the 12-month PFS rates of the two groups were 23.
    8% and 6.
    0%, respectively, and the PFS curves showed early separation and persisted
    at about 2 months.



    Figure PFS analysis


    The ORR of the serplulimab group reached 80.
    2%, which was nearly 10%
    higher than that of the control group.
    Compared with the ORR of 60%~70% of the same type of research, serplulimab treatment has made a large breakthrough, suggesting that a wider population can benefit from it2,3
    .
    The 6-month and 12-month DOR rates in the serplulimab group were significantly better than those in the control group (45.
    1% vs 17.
    1%, 24.
    0% vs 8.
    9%), and the median DOR of the two groups was 5.
    6 months vs 3.
    2 months, respectively, demonstrating the persistent antitumor activity
    of serplulimab.


    Table Mitigation Analysis



    Safe and co-escorted! With controllable peace of mind, serplulimab is expected to redefine the new standard of ES-SCLC immunotherapy


    The safety profile of serplulimab was controllable, with similar rates of adverse events (AEs) in the two groups, with 82.
    5% versus 80.
    1% of TEAEs occurring during the ≥ 3rd grade treatment period, 33.
    2% vs 27.
    6% of the TRAEs associated with serplulimab/placebo in ≥grade 3, and 4.
    9% vs 4.
    1% of TRAEs leading to discontinuation and 0.
    8% vs 0.
    5% of deaths related to study drugs, respectively , there was no difference
    between the two groups.


    Table Adverse Event Analysis



    JAMA is the top journal in the global medical field, with the improvement of the research level of Chinese researchers, the development of independent innovative drugs in China, in recent years, China's original research has also begun to win JAMA, but in the field of SCLC immunotherapy This is the first research favored by JAMA, the level and clinical significance of this research has been affirmed by international peers, PD-1 inhibitor serplulimab will release great potential
    in the clinical application of ES-SCLC in China and even the world 。 Domestic innovative drugs continue to speak out on the international stage, injecting new blood into the global progress of new drugs, bringing new breakthroughs, and demonstrating national self-confidence and strength
    .


    Based on the excellent results of the ASTRUM-005 study, the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Small Cell Lung Cancer 2022 Edition" updated and released in April this year has been regarded as a level III recommendation for ES-SCLC therapy (class 1A evidence).

    At the same time, the marketing registration application for the first-line therapeutic indication of serplulimab ES-SCLC has been accepted by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, and it is expected that it will add new options
    that are efficient, safe and accessible to ES-SCLC patients.


    ASTRUM-005 research leading PI Professor Cheng Ying


    Professor Ying Cheng

    First-class professor, national key clinical specialty discipline leader

    Doctoral supervisor, postdoctoral workstation supervisor

    Enjoy the special allowance of the State Council, and the Ministry of Health has made outstanding contributions to young and middle-aged experts

    Secretary of the Party Committee of Jilin Cancer Hospital

    Director of Jilin Cancer Center

    Director of the Integrated Diagnosis and Treatment Center for Clinical Research of Malignant Tumors of Jilin Cancer Hospital

    Director of Jilin Provincial Lung Cancer Diagnosis and Treatment Center

    Vice President of Chinese Society of Clinical Oncology (CSCO).

    Chairman of the CSCO Small Cell Lung Cancer Professional Committee

    Chairman-designate of the CSCO Clinical Research Expert Committee

    Chairman-elect of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association

    Vice Chairman of the CSCO Non-Small Cell Lung Cancer Professional Committee

    Vice Chairman of CSCO Tumor Big Data Expert Committee

    Vice Chairman of the Lung Cancer Committee of the Oncology Branch of the Chinese Medical Association

    Vice Chairman of the Multidisciplinary Diagnosis and Treatment Committee of Oncology of the Chinese Medical Doctor Association

    Vice Chairman of the Lung Cancer Training Professional Committee of the Chinese Medical Doctor Association

    Member of the expert group on standardized diagnosis and treatment of common tumors of the National Health and Family Planning Commission

    Chairman of the Oncologist Branch of Jilin Medical Doctor Association

    Chairman of the Oncology Professional Committee of Jilin Medical Association


    References:

    1.
    Cheng Y, Han L, Wu L, et al.
    Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial [J].
    JAMA.
    2022; 328(12):1223-1232.

    2.
    Stephen V Liu, Martin Reck, Aaron S Mansfield , et al.
    Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) [J].
    J Clin Oncol.
    2021 Feb 20; 39(6):619-630.

    3.
    Jonathan W Goldman, Mikhail Dvorkin , Yuanbin Chen, et al.
    Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial [J].
    Lancet Oncol.
    2021 Jan; 22(1):51-65.

    4.
    Rudin CM, Awad MM, Navarro A,et al.
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study[J].
    J Clin Oncol.
    2020 Jul 20; 38(21):2369-2379.

    5.
    Ticiana Leal, Yating Wang, Afshin Dowlati, et al.
    Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC) : ECOG-ACRIN EA5161.
    2020 ASCO Abstract 9000.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.